The BioCentury Show Ep. 78 - Biotech’s New Normal: SR One’s Simeon George on Adapting to Market Constraints
Feb 20, 2025
Simeon George, CEO and managing partner of SR One and biotech investor/founder, gives a candid take on adapting to a tougher capital market. He discusses valuation realism, prioritizing programs and when to pivot. He outlines proactive sourcing, China’s accelerating ecosystem, and building transatlantic companies. Practical strategy and capital discipline are central themes.
AI Snips
Chapters
Transcript
Episode notes
Reorient For The New Normal
- Reorient your business model to operate with higher cost of capital and fewer IPO exits.
- Make hard decisions early: cut programs, prioritize projects, or partner sooner to conserve capital.
Prioritize Projects Relentlessly
- Review all programs and allocate finite capital to highest-return projects only.
- Prioritize two projects over four, deprioritize others, and consider earlier partnerships to stretch resources.
Let CEOs Drive Strategy
- Trust and empower CEOs to decide pivots using on-the-ground knowledge and judgement.
- Use boards to pressure-test assumptions but avoid micromanaging strategy from investors.